Aspirin and colorectal cancer prevention in Lynch syndrome
A partir des résultats de l'essai randomisé CPP2 (861 participants ; durée médiane de suivi : 55,7 mois), cette étude évalue l'effet chimiopréventif de l'aspirine sur le cancer colorectal héréditaire sans polypose (syndrome de Lynch)
More than 600 000 people worldwide die of colorectal cancer annually, 1 making development of effective preventive agents for this disease a high priority. One of the most promising such agents, aspirin, is the subject of a major report in The Lancet by John Burn and colleagues. 2 In previous work, four placebo-controlled randomised trials showed that aspirin reduced risk of colorectal adenomas, precursor of almost all colorectal cancers, in patients with a history of adenoma or colorectal cancer.
The Lancet , éditorial, 2010